Search Results
CLO20-050: Effect of Tumor Grade on Neoadjuvant Treatment Outcome in Esophageal Cancer
Jordan McDonald, Rutika Mehta, Sarah Hoffe, and Jose Pimiento
Plenary Session—The Patient Journey: Cancer Survivor Care
Presented by: Shannon M. Ansbaugh, Gary Deng, Rev. George F. Handzo, and Karen L. Syrjala
Moderated by: Jessica R. Bauman
without cancer. Dr. Syrjala noted that some of these outcomes, such as symptoms of post-traumatic stress (different from a full diagnosis of PTSD) can persist for 10 to 15 years after diagnosis. Figure 1. Mental health outcomes in post
NCCN Task Force Report: Positron Emission Tomography (PET)/Computed Tomography (CT) Scanning in Cancer
Donald A. Podoloff, Ranjana H. Advani, Craig Allred, Al B. Benson III, Elizabeth Brown, Harold J. Burstein, Robert W. Carlson, R. Edward Coleman, Myron S. Czuczman, Dominique Delbeke, Stephen B. Edge, David S. Ettinger, Frederic W. Grannis Jr., Bruce E. Hillner, John M. Hoffman, Krystyna Kiel, Ritsuko Komaki, Steven M. Larson, David A. Mankoff, Kenneth E. Rosenzweig, John M. Skibber, Joachim Yahalom, JQ Michael Yu, and Andrew D. Zelenetz
any prior knowledge of the results of other studies is essential. Finally, assessing how the results of the PET scan impact patient management and improve health outcomes is important. Health outcomes include not only survival but also quality of life
HSR22-178: Real World Outcomes of Cancer Patients With SARS-CoV-2 Infection Receiving Monoclonal Antibodies
Alexa Wilden, Aishwarya Sannareddy, Hetal Patel, Shraddha Kansagra, Gurbakhash Kaur, Praveen Ramakrishnan, Prapti Patel, Ansh Mehta, and Ankit Kansagra
CLO21-028: Clinical Outcomes for Advanced Hepatocellular Carcinoma Patients Treated With Systemic Agents in Real-World Practice
Karine Tawagi, Diana Maslov, Madhav KC, Danny Markabawi, Suresh Mukkamala, Fady Farag, Helen Yuan, Adi Bamnolker, Rula Saeed, Zoe Blake, Marc Matrana, and Daniel Johnson
CLO22-047: Outcomes of SARS-COV-2 mRNA-1273 Vaccine in Cancer Patients: Seroconversion and Adverse Events
Javier David Benitez Fuentes, Alicia de Luna Aguilar, Alejandro Francisco Jimenez Ortega, Alberto Delgado-Iribarren Garcia-Campero, Elvira Baos Muñoz, Sara Gil Useros, and Pedro Perez Segura
HSR20-092: “Write to Recover”: The Impact of Group Led Creative Writing on Physical Health Outcomes in Cancer Patients
Courtney Ann Kramer, Darya S. Nesterova, Junjia Zhu, Monali Vasekar, Jolene Collins, Cristina Truica, Aditya Joshi, Michael Hayes, Erika F. H. Saunders, Joseph J. Drabick, and Monika Joshi
Independent Prognostic Value of Serum Markers in Diffuse Large B-Cell Lymphoma in the Era of the NCCN-IPI
Thomas Melchardt, Katharina Troppan, Lukas Weiss, Clemens Hufnagl, Daniel Neureiter, Wolfgang Tränkenschuh, Konstantin Schlick, Florian Huemer, Alexander Deutsch, Peter Neumeister, Richard Greil, Martin Pichler, and Alexander Egle
with an independent and reproducible influence on the clinical outcome may further improve the NCCN-IPI. Patients and Methods This retrospective analysis was approved by the Ethics Committee of the provincial government of Salzburg, Austria (415
Use of Direct Oral Anticoagulants for Treating Venous Thromboembolism in Patients With Cancer
Gerald A. Soff
was given for at least 6 months and up to 12 months. 3 For the primary outcome measure—a composite of recurrent VTE or major bleeding during the 12 months after randomization—edoxaban proved to be noninferior to LMWH ( Figure 2 ). “The hazard ratios
A Systematic Review of Clinical Decision Support Systems for Clinical Oncology Practice
Pamala A. Pawloski, Gabriel A. Brooks, Matthew E. Nielsen, and Barbara A. Olson-Bullis
-based standardization of cancer care, improving care delivery and patient outcomes. CDS tools have been incorporated across the patient care spectrum, encompassing prevention, diagnosis, and clinical monitoring. Common roles for CDS include computerized physician order
